Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.09. | Revelation Biosciences files to sell 13.07M shares of common stock by selling shareholders | 4 | Seeking Alpha | ||
11.09. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds | 228 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
10.09. | Revelation Biosciences: Wirkstoffkandidat Gemini zeigt vielversprechende Ergebnisse bei chronischer Nierenerkrankung | 2 | Investing.com Deutsch | ||
10.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data | 334 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
09.09. | Revelation Biosciences, Inc.: Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data | 253 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
09.09. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 6 | SEC Filings | ||
09.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study | 197 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
08.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
08.08. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
09.07. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
01.07. | Revelation Biosciences to implement 1-for-3 reverse stock split | 1 | Investing.com | ||
01.07. | Revelation Biosciences plant Aktienzusammenlegung im Verhältnis 1:3 | 1 | Investing.com Deutsch | ||
01.07. | Revelation Biosciences, Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 | 173 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of... ► Artikel lesen | |
25.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 4 | SEC Filings | ||
04.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
29.05. | Revelation Biosciences sets terms for $4 million public offering | 3 | Investing.com | ||
28.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
23.05. | Revelation Biosciences board member steps down amid new focus | 2 | Investing.com | ||
23.05. | REVELATION BIOSCIENCES, INC. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
20.05. | REVELATION BIOSCIENCES, INC. - S-1, General form for registration of securities | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,525 | +0,14 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 26,620 | 0,00 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
DISC MEDICINE | 65,86 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,500 | -0,36 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
BIONTECH | 89,10 | -0,11 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
EVOTEC | 6,656 | +0,67 % | Von Abnehmspritzen bis Krebstherapie: Diese Plattform-Technologie greift gleich mehrere Milliardenmärkte an! | Anzeige / WerbungDie moderne Medizin steht vor einer gewaltigen Aufgabe: Immer mehr Menschen leiden an sogenannten Wohlstandserkrankungen wie Adipositas, Diabetes, Multiple Sklerose oder MASH, der gefürchteten... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 5,220 | +6,97 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
KYMERA THERAPEUTICS | 56,02 | 0,00 % | Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline | ||
4D MOLECULAR THERAPEUTICS | 8,670 | 0,00 % | 4D Molecular Therapeutics, Inc. - 8-K, Current Report | ||
JYONG BIOTECH | 52,00 | 0,00 % | Jyong Biotech Ltd.: Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards | ||
MOONLAKE IMMUNOTHERAPEUTICS | 8,340 | +11,80 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 28,260 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
LENZ THERAPEUTICS | 48,250 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen |